Complete resection and adjuvant chemotherapy improve outcomes in resected biliary tract cancers (BTCs), but improved treatment options are still needed, according to results published in Therapeutic Advances in Medical Oncology. Tharani Krishnan, MBBS, FRACP, MHLM, and colleagues conducted a review of 594 patients, including 416 with disease recurrence, to examine treatment failure in gallbladder cancers or cholangiocarcinoma. Adjuvant chemo – therapy was administered in 51% of patients. Ad – ditionally, one-third of patients failed to complete all planned treatment cycles. Median overall survival was higher with complete versus incomplete resec – tion (31.6 vs 18 months), with a marked improve – ment with re-resection (29.4 vs 19 months). Pa – tients who received adjuvant therapy saw increased survival (HR, 0.79), however, only 25% of the more recent cohort (2017–2019) achieved R0 re – section and completed adjuvant chemotherapy. The findings highlight “the high recurrence rates seen with BTCs despite optimal surgical resection” as well as “the need to find improved treatment pathways,” Dr. Krishnan and colleagues wrote.